S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS

Detalles Bibliográficos
Autores principales: Telen, M, Saraf, S, Cruz, K, Idowu, M, Kalfa, T, Osunkwo, I, Hagar, R, Geib, J, Forsyth, S, Schroeder, P, Wu, E, Kelly, P, Brown, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811875/
http://dx.doi.org/10.1097/01.HS9.0000821404.03661.11
_version_ 1784644526229422080
author Telen, M
Saraf, S
Cruz, K
Idowu, M
Kalfa, T
Osunkwo, I
Hagar, R
Geib, J
Forsyth, S
Schroeder, P
Wu, E
Kelly, P
Brown, R
author_facet Telen, M
Saraf, S
Cruz, K
Idowu, M
Kalfa, T
Osunkwo, I
Hagar, R
Geib, J
Forsyth, S
Schroeder, P
Wu, E
Kelly, P
Brown, R
author_sort Telen, M
collection PubMed
description
format Online
Article
Text
id pubmed-8811875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-88118752022-02-22 S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS Telen, M Saraf, S Cruz, K Idowu, M Kalfa, T Osunkwo, I Hagar, R Geib, J Forsyth, S Schroeder, P Wu, E Kelly, P Brown, R Hemasphere Oral Presentations Lippincott Williams & Wilkins 2022-01-31 /pmc/articles/PMC8811875/ http://dx.doi.org/10.1097/01.HS9.0000821404.03661.11 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Presentations
Telen, M
Saraf, S
Cruz, K
Idowu, M
Kalfa, T
Osunkwo, I
Hagar, R
Geib, J
Forsyth, S
Schroeder, P
Wu, E
Kelly, P
Brown, R
S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
title S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
title_full S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
title_fullStr S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
title_full_unstemmed S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
title_short S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
title_sort s109: activation of pyruvate kinase-r with etavopivat (ft-4202) is well tolerated, improves anemia, and decreases intravascular hemolysis in patients with sickle cell disease treated for up to 12 weeks
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811875/
http://dx.doi.org/10.1097/01.HS9.0000821404.03661.11
work_keys_str_mv AT telenm s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT sarafs s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT cruzk s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT idowum s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT kalfat s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT osunkwoi s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT hagarr s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT geibj s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT forsyths s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT schroederp s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT wue s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT kellyp s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks
AT brownr s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks

Ejemplares similares